正海生物：公司在钙硅生物陶瓷口腔骨修复材料取证上市前提前规划建设了产品独立生产线

Core Viewpoint - The company is effectively managing its production capacity to meet market demand for its products, particularly in the field of calcium silicate bioceramics for dental bone repair [2]. Group 1: Production Capacity - The company reported that its overall production capacity is operating within a normal and efficient range, responding to customer order demands [2]. - A dedicated production line for calcium silicate bioceramics has been established prior to product certification and market launch, ensuring stable and efficient production [2]. Group 2: Market Demand - The production capacity of the new product line is sufficient to meet the anticipated market demand for calcium silicate bioceramics [2].